View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT redu...

A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew’s leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the st...

 PRESS RELEASE

Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ C...

Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹* The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical sta...

Smith & Nephew: 1 director

A director at Smith & Nephew sold 25,222 shares at 1,070p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technolog...

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025   Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Robotics: Optimizing and personalizing surgery With CORIOGRAPH◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnosti...

 PRESS RELEASE

Smith+Nephew to highlight breakthrough Sports Medicine technologies fo...

Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Spatial Surgery Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical inn...

 PRESS RELEASE

New report confirms Smith+Nephew’s OXINIUM™ Technology is the best per...

New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew’s proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period...

 PRESS RELEASE

Smith+Nephew is pioneering Spatial Surgery – a defining new Sports Med...

Smith+Nephew is pioneering Spatial Surgery – a defining new Sports Medicine category pushing the boundaries of technology and procedural innovation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its pioneering efforts to develop technology in the field of Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation. We envision Spatial Surgery as an opportunity to provide personalized planning, augmented reality and real-time data processing into platforms that interpret the surgical field intraoperatively.  Smith+Nephew has su...

 PRESS RELEASE

Smith+Nephew and UFC to host first-of-its-kind medical education cours...

Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes Healthcare professionals are invited to register for the livestream option as a courtesy  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the inaugural Smith+Nephew UFC Combat Sports Medicine Course to be held in Las Vegas, Nevada from February 20-21, 2025. The course will be chaired by Dr. Michael Banffy from the Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, California and features a roster of world-renowned medical experts...

 PRESS RELEASE

Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Mo...

Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable’ Evidence Bar™ ratings from ECRI for pressure injury prevention Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most recently published clinical...

Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...

 PRESS RELEASE

Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Servi...

Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planni...

 PRESS RELEASE

Smith+Nephew expands AETOS™ Shoulder System with new stemless option f...

Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless).  AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.1 It is designed to maximize metaphyseal fixation and stability with an inl...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch